{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T09:11:49Z","timestamp":1777885909267,"version":"3.51.4"},"reference-count":101,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,13]],"date-time":"2025-07-13T00:00:00Z","timestamp":1752364800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82272845"],"award-info":[{"award-number":["82272845"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007129","name":"Shandong Province Natural Science Foundation","doi-asserted-by":"publisher","award":["ZR2023LZL001"],"award-info":[{"award-number":["ZR2023LZL001"]}],"id":[{"id":"10.13039\/501100007129","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.critrevonc.2025.104853","type":"journal-article","created":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T16:22:45Z","timestamp":1752596565000},"page":"104853","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Additions and subtractions of radiotherapy in patients with oligometastatic non-small cell lung cancer under the era of immunotherapy"],"prefix":"10.1016","volume":"214","author":[{"given":"Ziran","family":"Sun","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junxu","family":"Wen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenxing","family":"Cui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Minghao","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yankang","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2737-5905","authenticated-orcid":false,"given":"Xiangjiao","family":"Meng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.critrevonc.2025.104853_bib1","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.trecan.2020.01.005","article-title":"Hyperprogression and immunotherapy: fact, fiction, or alternative fact?","volume":"6","author":"Adashek","year":"2020","journal-title":"Trends Cancer"},{"key":"10.1016\/j.critrevonc.2025.104853_bib2","doi-asserted-by":"crossref","first-page":"2766","DOI":"10.21037\/tlcr-20-1117","article-title":"A narrative review of combined stereotactic ablative radiotherapy and immunotherapy in metastatic non-small cell lung cancer","volume":"10","author":"Akanda","year":"2021","journal-title":"Transl. Lung Cancer Res"},{"key":"10.1016\/j.critrevonc.2025.104853_bib3","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.ijrobp.2023.02.011","article-title":"Ablative radiation therapy for oligometastatic egfr-mutated non-small cell lung cancer: who, why, when, and how?","volume":"116","author":"Amini","year":"2023","journal-title":"Int. J. Radiat. Oncol. *Biol. *Phys."},{"key":"10.1016\/j.critrevonc.2025.104853_bib4","unstructured":"Bai Y, Yang W, K\u00e4smann L, Sorich MJ, Tao H, Hu Y. Immunotherapy for advanced non-small cell lung cancer with negative programmed death-ligand 1 expression: a literature review."},{"key":"10.1016\/j.critrevonc.2025.104853_bib5","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1097\/PPO.0000000000000438","article-title":"Prognostic and predictive biomarkers in oligometastatic disease","volume":"26","author":"Barnum","year":"2020","journal-title":"Cancer J."},{"key":"10.1016\/j.critrevonc.2025.104853_bib6","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1016\/j.ijrobp.2023.11.040","article-title":"Combining dual checkpoint immunotherapy with ablative radiation to all sites of oligometastatic non-small cell lung cancer: toxicity and efficacy results of a phase 1b trial","volume":"118","author":"Bassetti","year":"2024","journal-title":"Int. J. Radiat. Oncol. *Biol. *Phys."},{"key":"10.1016\/j.critrevonc.2025.104853_bib7","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1001\/jamaoncol.2019.1449","article-title":"Pembrolizumab after completion of locally ablative therapy for oligometastatic non-small cell lung cancer: a phase 2 trial","volume":"5","author":"Bauml","year":"2019","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.critrevonc.2025.104853_bib8","doi-asserted-by":"crossref","first-page":"5127","DOI":"10.3390\/cancers15215127","article-title":"Impact of waiting response evaluation to first-line systemic therapy before considering local ablative therapy in metastatic non-small-cell lung cancer","volume":"15","author":"Belaidi","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.critrevonc.2025.104853_bib9","doi-asserted-by":"crossref","first-page":"210","DOI":"10.3389\/fonc.2017.00210","article-title":"Radiotherapy for oligometastatic lung cancer","volume":"7","author":"Bergsma","year":"2017","journal-title":"Front Oncol."},{"key":"10.1016\/j.critrevonc.2025.104853_bib10","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.jtho.2021.08.019","article-title":"A phase 1 trial of concurrent or sequential ipilimumab, nivolumab, and stereotactic body radiotherapy in patients with stage IV NSCLC study","volume":"17","author":"Bestvina","year":"2022","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104853_bib11","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.lungcan.2021.11.009","article-title":"Pathologic responses in oligometastatic NSCLC patients treated with neoadjuvant immune checkpoint blockade with and without chemotherapy followed by surgery","volume":"164","author":"Boch","year":"2022","journal-title":"Lung Cancer"},{"key":"10.1016\/j.critrevonc.2025.104853_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2021.103378","article-title":"Treatment strategies for locally advanced non-small cell lung cancer in elderly patients: translating scientific evidence into clinical practice","volume":"163","author":"Bonanno","year":"2021","journal-title":"Crit. Rev. Oncol. \/Hematol."},{"key":"10.1016\/j.critrevonc.2025.104853_bib13","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1016\/j.ijrobp.2023.09.052","article-title":"Impact on pulmonary function in a randomized trial of single-fraction and multifraction stereotactic body radiation therapy for pulmonary oligometastatic disease: an analysis of TROG 13.01 (SAFRON II)","volume":"118","author":"Bucknell","year":"2024","journal-title":"Int. J. Radiat. Oncol. *Biol. *Phys."},{"key":"10.1016\/j.critrevonc.2025.104853_bib14","doi-asserted-by":"crossref","first-page":"531","DOI":"10.6004\/jnccn.2021.7117","article-title":"Optimize local therapy for oligometastatic and oligoprogressive non-small cell lung cancer to enhance survival","volume":"20","author":"Chang","year":"2022","journal-title":"J. Natl. Compr. Canc Netw."},{"key":"10.1016\/j.critrevonc.2025.104853_bib15","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1016\/j.ijrobp.2022.06.073","article-title":"Conditional survival of patients with extracranial oligometastatic treated with stereotactic body radiation therapy: an international consortium study","volume":"114","author":"Chen","year":"2022","journal-title":"Int. J. Radiat. Oncol. *Biol. *Phys."},{"key":"10.1016\/j.critrevonc.2025.104853_bib16","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1111\/1759-7714.14312","article-title":"Local consolidative therapy for synchronous oligometastatic non-small cell lung cancer treated with first-line pembrolizumab: a retrospective observational study","volume":"13","author":"Chen","year":"2022","journal-title":"Thorac. Cancer"},{"key":"10.1016\/j.critrevonc.2025.104853_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2024.110235","article-title":"Cancer-specific dose and fractionation schedules in stereotactic body radiotherapy for oligometastatic disease: an interim analysis of the EORTC-ESTRO E2-RADIatE OligoCare study","volume":"195","author":"Christ","year":"2024","journal-title":"Radiother. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104853_bib18","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/j.ijrobp.2022.06.100","article-title":"Imaging-based prevalence of oligometastatic disease: a single-center cross-sectional study","volume":"114","author":"Christ","year":"2022","journal-title":"Int. J. Radiat. Oncol. *Biol. *Phys."},{"key":"10.1016\/j.critrevonc.2025.104853_bib19","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1200\/JCO.21.02528","article-title":"Management of stage III non\u2013small-cell lung cancer: ASCO guideline","volume":"40","author":"Daly","year":"2022","journal-title":"JCO"},{"key":"10.1016\/j.critrevonc.2025.104853_bib20","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1016\/j.jtho.2019.07.025","article-title":"Definition of synchronous oligometastatic non-small cell lung cancer-a consensus report","volume":"14","author":"Dingemans","year":"2019","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104853_bib21","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.canlet.2020.12.045","article-title":"Radiotherapy, immunotherapy, and the tumour microenvironment: Turning an immunosuppressive milieu into a therapeutic opportunity","volume":"502","author":"Donlon","year":"2021","journal-title":"Cancer Lett."},{"key":"10.1016\/j.critrevonc.2025.104853_bib22","doi-asserted-by":"crossref","unstructured":"Duda, D., Gkika, E., Firat, E., Adebahr, S., Graf, E., Eichhorst, A., , 2023. A prospective study of immune responses in patients with lung metastases treated with stereotactic body radiotherapy with or without concurrent systemic treatment. \u3008https:\/\/www.researchsquare.com\/article\/rs-3547043\/v1\u3009.","DOI":"10.21203\/rs.3.rs-3547043\/v1"},{"key":"10.1016\/j.critrevonc.2025.104853_bib23","doi-asserted-by":"crossref","first-page":"4353","DOI":"10.1002\/cncr.33083","article-title":"A phase 2 trial of consolidation pembrolizumab following concurrent chemoradiation for patients with unresectable stage III non-small cell lung cancer: Hoosier Cancer Research Network LUN 14-179","volume":"126","author":"Durm","year":"2020","journal-title":"Cancer"},{"key":"10.1016\/j.critrevonc.2025.104853_bib24","unstructured":"Efficacy and safety of combining radiotherapy with immune checkpoint inhibitors in patients with advanced non-small cell lung cancer: a real-world study - PubMed [Internet]. https:\/\/pubmed.ncbi.nlm.nih.gov\/39431538\/."},{"key":"10.1016\/j.critrevonc.2025.104853_bib25","first-page":"15","article-title":"Non\u2013small cell lung cancer, version 5.2017","author":"Ettinger","year":"2017","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"10.1016\/j.critrevonc.2025.104853_bib26","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.ejca.2021.07.035","article-title":"Prospective trial of immuno(chemo)therapy before resection, definitive chemoradiotherapy or palliative therapy in patients with locally advanced or oligometastatic non-small cell lung cancer without a primary curative option","volume":"156","author":"Faehling","year":"2021","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.critrevonc.2025.104853_bib27","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.radonc.2021.08.005","article-title":"Increased biologically effective dose (BED) to the primary tumor is associated with improved survival in patients with oligometastatic NSCLC","volume":"163","author":"Farooqi","year":"2021","journal-title":"Radiother. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104853_bib28","doi-asserted-by":"crossref","first-page":"5700","DOI":"10.3390\/cancers14225700","article-title":"The multidisciplinary approach in stage III non-small cell lung cancer over ten years: from radiation therapy optimisation to innovative systemic treatments","volume":"14","author":"Ferro","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.critrevonc.2025.104853_bib29","doi-asserted-by":"crossref","first-page":"1976","DOI":"10.1056\/NEJMoa1716078","article-title":"Neoadjuvant PD-1 blockade in resectable lung cancer","volume":"378","author":"Forde","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2025.104853_bib30","doi-asserted-by":"crossref","first-page":"10247","DOI":"10.1074\/jbc.271.17.10247","article-title":"MadedduL null. Cloning and sequence analysis of genes coding for paramecium secretory granule (trichocyst) proteins. A unique protein fold for a family of polypeptides with different primary structures","volume":"271","author":"Gautier","year":"1996","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.critrevonc.2025.104853_bib31","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1016\/S1470-2045(16)30532-0","article-title":"Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study","volume":"17","author":"Gomez","year":"2016","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2025.104853_bib32","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1016\/S1470-2045(19)30718-1","article-title":"Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation","volume":"21","author":"Guckenberger","year":"2020","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2025.104853_bib33","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1016\/S1470-2045(19)30718-1","article-title":"Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation","volume":"21","author":"Guckenberger","year":"2020","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2025.104853_bib34","doi-asserted-by":"crossref","first-page":"2577","DOI":"10.1158\/0008-5472.CAN-20-3337","article-title":"(Oligo)metastasis as a Spectrum of Disease","volume":"81","author":"Gutiontov","year":"2021","journal-title":"Cancer Res."},{"key":"10.1016\/j.critrevonc.2025.104853_bib35","doi-asserted-by":"crossref","first-page":"5823","DOI":"10.3390\/cancers13225823","article-title":"Oligoprogression in non-small cell lung cancer","volume":"13","author":"Harada","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.critrevonc.2025.104853_bib36","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2025.104676","article-title":"Consolidative radiotherapy in oligometastatic and oligoprogressive NSCLC: a systematic review","volume":"210","author":"Hasan","year":"2025","journal-title":"Crit. Rev. Oncol. \/Hematol."},{"key":"10.1016\/j.critrevonc.2025.104853_bib37","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1200\/JCO.1995.13.1.8","article-title":"Oligometastases","volume":"13","author":"Hellman","year":"1995","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104853_bib38","unstructured":"Immunotherapy for advanced non-small cell lung cancer with negative programmed death-ligand 1 expression: a literature review - PubMed [Internet]. https:\/\/pubmed.ncbi.nlm.nih.gov\/38496691\/."},{"key":"10.1016\/j.critrevonc.2025.104853_bib39","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.prro.2023.04.004","article-title":"Treatment of oligometastatic non-small cell lung cancer: an ASTRO\/ESTRO clinical practice guideline","volume":"13","author":"Iyengar","year":"2023","journal-title":"Pract. Radiat. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104853_bib40","doi-asserted-by":"crossref","first-page":"8506","DOI":"10.1200\/JCO.2024.42.16_suppl.8506","article-title":"NRG-LU002: randomized phase II\/III trial of maintenance systemic therapy versus local consolidative therapy (LCT) plus maintenance systemic therapy for limited metastatic non-small cell lung cancer (NSCLC)","volume":"42","author":"Iyengar","year":"2024","journal-title":"JCO"},{"key":"10.1016\/j.critrevonc.2025.104853_bib41","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2017.3501","article-title":"Consolidative Radiotherapy for Limited Metastatic Non-Small-Cell Lung Cancer: A Phase 2 Randomized Clinical Trial","volume":"4","author":"Iyengar","year":"2018","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.critrevonc.2025.104853_bib42","unstructured":"Jasper K., Stiles B., McDonald F., Palma D.A. Practical management of oligometastatic non\u2013small-cell lung cancer."},{"key":"10.1016\/j.critrevonc.2025.104853_bib43","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2023.112947","article-title":"Treatment outcome of patients with synchronous oligometastatic non-small cell lung cancer in the immunotherapy era: Analysis of a real-life intention-to-treat population","volume":"190","author":"Jongbloed","year":"2023","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.critrevonc.2025.104853_bib44","doi-asserted-by":"crossref","first-page":"4442","DOI":"10.1111\/cas.14605","article-title":"Efficacy of local therapy for oligoprogressive disease after programmed cell death 1 blockade in advanced non-small cell lung cancer","volume":"111","author":"Kagawa","year":"2020","journal-title":"Cancer Sci."},{"key":"10.1016\/j.critrevonc.2025.104853_bib45","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.ijrobp.2022.06.068","article-title":"Predictors of pneumonitis in combined thoracic stereotactic body radiation therapy and immunotherapy","volume":"114","author":"Korpics","year":"2022","journal-title":"Int J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.critrevonc.2025.104853_bib46","doi-asserted-by":"crossref","first-page":"5792","DOI":"10.1158\/1078-0432.CCR-17-3620","article-title":"The integration of radiotherapy with immunotherapy for the treatment of non-small cell lung cancer","volume":"24","author":"Ko","year":"2018","journal-title":"Clin. Cancer Res"},{"key":"10.1016\/j.critrevonc.2025.104853_bib47","doi-asserted-by":"crossref","first-page":"e534","DOI":"10.1016\/S1470-2045(18)30571-0","article-title":"Use of modern imaging methods to facilitate trials of metastasis-directed therapy for oligometastatic disease in prostate cancer: a consensus recommendation from the EORTC Imaging Group","volume":"19","author":"Lecouvet","year":"2018","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2025.104853_bib48","article-title":"Local ablative therapy combined with pembrolizumab in patients with synchronous oligometastatic non-small cell lung cancer: a recursive partitioning analysis","author":"Lee","year":"2024","journal-title":"Int. J. Radiat. Oncol. *Biol. *Phys."},{"key":"10.1016\/j.critrevonc.2025.104853_bib49","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.radonc.2020.04.003","article-title":"Defining oligometastatic disease from a radiation oncology perspective: an ESTRO-ASTRO consensus document","volume":"148","author":"Lievens","year":"2020","journal-title":"Radio. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104853_bib50","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.radonc.2020.04.003","article-title":"Defining oligometastatic disease from a radiation oncology perspective: an ESTRO-ASTRO consensus document","volume":"148","author":"Lievens","year":"2020","journal-title":"Radiother. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104853_bib51","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1186\/s13045-018-0647-8","article-title":"Abscopal effect of radiotherapy combined with immune checkpoint inhibitors","volume":"11","author":"Liu","year":"2018","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104853_bib52","unstructured":"Li Q, Ma H, Zheng R, Ling Y, Cai L, Zhang Y, et al., Durvalumab combined with chemotherapy and radiotherapy in patients with oligometastatic non-small cell lung cancer (SABRcure)."},{"key":"10.1016\/j.critrevonc.2025.104853_bib53","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1200\/JCO.2017.76.2229","article-title":"Safety and Clinical Activity of Pembrolizumab and Multisite Stereotactic Body Radiotherapy in Patients With Advanced Solid Tumors","volume":"36","author":"Luke","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104853_bib54","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1016\/j.jtho.2022.09.227","article-title":"Local Treatments of Oligometastatic and Oligoprogressive NSCLC Should Not Become the Standard of Care","volume":"18","author":"Macbeth","year":"2023","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104853_bib55","doi-asserted-by":"crossref","first-page":"1039157","DOI":"10.3389\/fimmu.2022.1039157","article-title":"The Effect of immunotherapy on oligometastatic non-small cell lung cancer patients by sites of metastasis","volume":"13","author":"Ma","year":"2022","journal-title":"Front Immunol."},{"key":"10.1016\/j.critrevonc.2025.104853_bib56","unstructured":"Memorial Sloan Kettering Cancer Center. PROMISE-005: A Phase II Randomized Study Assessing the Efficacy of Stereotactic Body Radiotherapy (SBRT) in Patients With Oligometastatic Breast or Lung Cancer [Internet]. clinicaltrials.gov; 2025 Feb. Report No.: NCT03808337. Available from: https:\/\/clinicaltrials.gov\/study\/NCT03808337."},{"key":"10.1016\/j.critrevonc.2025.104853_bib57","unstructured":"Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer - PubMed [Internet]. https:\/\/pubmed.ncbi.nlm.nih.gov\/20351327\/."},{"key":"10.1016\/j.critrevonc.2025.104853_bib58","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1186\/s12885-021-08851-z","article-title":"Phase II study of multidisciplinary therapy combined with pembrolizumab for patients with synchronous oligometastatic non-small cell lung cancer TRAP OLIGO study (WJOG11118L)","volume":"21","author":"Miyawaki","year":"2021","journal-title":"BMC Cancer"},{"key":"10.1016\/j.critrevonc.2025.104853_bib59","unstructured":"Multidisciplinary consensusstatement on the clinical management of patients with stage III non-small cell lung cancer | Clinical and Translational Oncology [Internet]. [cited 2024 Oct 26]. Available from: \u3008https:\/\/link.springer.com\/article\/10.1007\/s12094-019-02134-7\u3009."},{"key":"10.1016\/j.critrevonc.2025.104853_bib60","first-page":"1351","article-title":"Radiotherapy in combination with CD47 blockade elicits a macrophage-mediated abscopal effect. Nat","volume":"3","author":"Nishiga","year":"2022","journal-title":"Cancer"},{"key":"10.1016\/j.critrevonc.2025.104853_bib61","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.ijrobp.2022.04.050","article-title":"Characterization of Metastatic Non-Small Cell Lung Cancer and Oligometastatic Incidence in an Era of Changing Treatment Paradigms","volume":"114","author":"No","year":"2022","journal-title":"Int. J. Radiat. Oncol. *Biol. *Phys."},{"key":"10.1016\/j.critrevonc.2025.104853_bib62","doi-asserted-by":"crossref","first-page":"2830","DOI":"10.1200\/JCO.20.00818","article-title":"Stereotactic ablative radiotherapy for the comprehensive treatment of oligometastatic cancers: long-term results of the SABR-COMET phase II randomized trial","volume":"38","author":"Palma","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104853_bib63","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1016\/j.ijrobp.2014.04.007","article-title":"Definitive primary therapy in patients presenting with oligometastatic non-small cell lung cancer","volume":"89","author":"Parikh","year":"2014","journal-title":"Int. J. Radiat. Oncol. *Biol. *Phys."},{"key":"10.1016\/j.critrevonc.2025.104853_bib64","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/j.clon.2019.05.015","article-title":"The dandelion dilemma revisited for oligoprogression: treat the whole lawn or weed selectively?","volume":"31","author":"Patel","year":"2019","journal-title":"Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104853_bib65","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1056\/NEJMoa1810865","article-title":"Pembrolizumab plus chemotherapy for squamous non\u2013small-cell lung cancer","volume":"379","author":"Paz-Ares","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2025.104853_bib66","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.ijrobp.2018.06.400","article-title":"Long-term outcomes of a phase 2 Trial of chemotherapy with consolidative radiation therapy for oligometastatic non-small cell lung cancer","volume":"102","author":"Petty","year":"2018","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.critrevonc.2025.104853_bib67","unstructured":"Prior or concurrentradiotherapy and nivolumab immunotherapy in non-small cell lung cancer- PubMed [Internet].\u3008https:\/\/pubmed.ncbi.nlm.nih.gov\/31721446\/\u3009."},{"key":"10.1016\/j.critrevonc.2025.104853_bib68","unstructured":"Progress in Radiotherapy for Regional and Oligometastatic Disease in 2017- PubMed [Internet].\u3008https:\/\/pubmed.ncbi.nlm.nih.gov\/29452269\/\u3009."},{"key":"10.1016\/j.critrevonc.2025.104853_bib69","unstructured":"Radiation and checkpointblockade immunotherapy: radiosensitisation and potential mechanisms of synergy - PubMed [Internet]. \u3008https:\/\/pubmed.ncbi.nlm.nih.gov\/26433823\/\u3009."},{"key":"10.1016\/j.critrevonc.2025.104853_bib70","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1056\/NEJMoa1913662","article-title":"Overall survival with osimertinib in untreated, EGFR -mutated advanced NSCLC","volume":"382","author":"Ramalingam","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2025.104853_bib71","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus chemotherapy for PD-L1\u2013positive non\u2013small-cell lung cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.critrevonc.2025.104853_bib72","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1080\/0284186X.2018.1481292","article-title":"Stereotactic body radiation therapy (SBRT) improves local control and overall survival compared to conventionally fractionated radiation for stage I non-small cell lung cancer (NSCLC)","volume":"57","author":"Von Reibnitz","year":"2018","journal-title":"Acta Oncol."},{"key":"10.1016\/j.critrevonc.2025.104853_bib73","doi-asserted-by":"crossref","first-page":"3486","DOI":"10.21037\/tlcr-20-1065","article-title":"How to optimize the incorporation of immunotherapy in trials for oligometastatic non-small cell lung cancer: a narrative review","volume":"10","author":"Remon","year":"2021","journal-title":"Transl. Lung Cancer Res"},{"key":"10.1016\/j.critrevonc.2025.104853_bib74","doi-asserted-by":"crossref","first-page":"3801","DOI":"10.1038\/s41467-020-17670-y","article-title":"A decade of immune-checkpoint inhibitors in cancer therapy","volume":"11","author":"Robert","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.critrevonc.2025.104853_bib75","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2019\/9435389","article-title":"Radiotherapy for Melanoma: more than DNA Damage","volume":"2019","author":"Rogers","year":"2019","journal-title":"Dermatol. Res. Pract."},{"key":"10.1016\/j.critrevonc.2025.104853_bib76","doi-asserted-by":"crossref","first-page":"4125","DOI":"10.21873\/anticanres.16602","article-title":"Efficacy and toxicity of robotic stereotactic body radiotherapy of lung metastases in patients with oligometastatic disease","volume":"43","author":"Rosenbrock","year":"2023","journal-title":"Anticancer Res"},{"key":"10.1016\/j.critrevonc.2025.104853_bib77","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtho.2024.07.016","article-title":"Real-world acute toxicity and 90-day mortality in patients with stage I NSCLC treated with stereotactic body radiotherapy","author":"van Rossum","year":"2024","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104853_bib78","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1097\/PPO.0000000000000437","article-title":"Circulating tumor DNA biomarkers for early detection of oligometastasis","volume":"26","author":"Routman","year":"2020","journal-title":"Cancer J."},{"key":"10.1016\/j.critrevonc.2025.104853_bib79","doi-asserted-by":"crossref","first-page":"4838","DOI":"10.1016\/j.cell.2021.07.028","article-title":"Senescence-induced vascular remodeling creates therapeutic vulnerabilities in pancreas","volume":"184","author":"Ruscetti","year":"2021","journal-title":"Cancer Cell"},{"key":"10.1016\/j.critrevonc.2025.104853_bib80","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.21873\/invivo.11999","article-title":"High-dose radiotherapy for oligo-progressive NSCLC receiving EGFR tyrosine kinase inhibitors: real world data","volume":"34","author":"Santarpia","year":"2020","journal-title":"Vivo"},{"key":"10.1016\/j.critrevonc.2025.104853_bib81","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/j.jtho.2018.02.001","article-title":"Progress in radiotherapy for regional and oligometastatic disease in 2017","volume":"13","author":"Senan","year":"2018","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104853_bib82","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1002\/cac2.12226","article-title":"Combined treatment of non-small cell lung cancer using radiotherapy and immunotherapy: challenges and updates","volume":"41","author":"Shang","year":"2021","journal-title":"Cancer Commun."},{"key":"10.1016\/j.critrevonc.2025.104853_bib83","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/S1470-2045(17)30380-7","article-title":"Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial","volume":"18","author":"Shaverdian","year":"2017","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2025.104853_bib84","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1016\/j.ijrobp.2022.05.023","article-title":"Definitive local consolidative therapy for oligometastatic solid tumors: results from the lead-in phase of the randomized basket trial EXTEND","volume":"114","author":"Sherry","year":"2022","journal-title":"Int. J. Radiat. Oncol. *Biol. *Phys."},{"key":"10.1016\/j.critrevonc.2025.104853_bib85","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1001\/jamaoncol.2021.2939","article-title":"Single-fraction vs multifraction stereotactic ablative body radiotherapy for pulmonary oligometastases (SAFRON II): the trans tasman radiation oncology group 13.01 phase 2 randomized clinical trial","volume":"7","author":"Siva","year":"2021","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.critrevonc.2025.104853_bib86","unstructured":"Stereotactic body radiation therapy (SBRT) improves local control and overall survival compared to conventionally fractionated radiation for stage I non-small cell lung cancer (NSCLC) - PubMed [Internet].\u3008https:\/\/pubmed.ncbi.nlm.nih.gov\/29873277\/\u3009."},{"key":"10.1016\/j.critrevonc.2025.104853_bib87","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/S2213-2600(20)30391-X","article-title":"Pembrolizumab with or without radiotherapy for metastatic non-small-cell lung cancer: a pooled analysis of two randomised trials","volume":"9","author":"Theelen","year":"2021","journal-title":"Lancet Respir. Med"},{"key":"10.1016\/j.critrevonc.2025.104853_bib88","unstructured":"Time to abandonsingle-site irradiation for inducing abscopal effects- PubMed [Internet]. \u3008https:\/\/pubmed.ncbi.nlm.nih.gov\/30401936\/\u3009."},{"key":"10.1016\/j.critrevonc.2025.104853_bib89","doi-asserted-by":"crossref","first-page":"47","DOI":"10.5694\/mja2.12046","article-title":"Radiotherapy and immunotherapy: a synergistic effect in cancer care","volume":"210","author":"Turgeon","year":"2019","journal-title":"Med J. Aust."},{"key":"10.1016\/j.critrevonc.2025.104853_bib90","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/j.jtho.2023.05.003","article-title":"Local treatments of oligometastatic and oligoprogressive NSCLC should become the standard of care","volume":"18","author":"Videtic","year":"2023","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104853_bib91","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/j.jtho.2023.05.003","article-title":"Local treatments of oligometastatic and oligoprogressive NSCLC should become the standard of care","volume":"18","author":"Videtic","year":"2023","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104853_bib92","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1093\/jnci\/djac015","article-title":"Randomized trial of first-line tyrosine kinase inhibitor with or without radiotherapy for synchronous oligometastatic EGFR -mutated non-small cell lung cancer","volume":"115","author":"Wang","year":"2023","journal-title":"JNCI J. Natl. Cancer Institute"},{"key":"10.1016\/j.critrevonc.2025.104853_bib93","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1038\/nrclinonc.2016.211","article-title":"Radiotherapy and immunotherapy: a beneficial liaison?","volume":"14","author":"Weichselbaum","year":"2017","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104853_bib94","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001001","article-title":"Pembrolizumab with or without radiation therapy for metastatic non-small cell lung cancer: a randomized phase I\/II trial","volume":"8","author":"Welsh","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.critrevonc.2025.104853_bib95","doi-asserted-by":"crossref","first-page":"2242","DOI":"10.1002\/cncr.30058","article-title":"Clinical and molecular markers of long-term survival after oligometastasis-directed stereotactic body radiotherapy (SBRT)","volume":"122","author":"Wong","year":"2016","journal-title":"Cancer"},{"key":"10.1016\/j.critrevonc.2025.104853_bib96","doi-asserted-by":"crossref","first-page":"4533","DOI":"10.3390\/ijms25084533","article-title":"Novel blood biomarkers for response prediction and monitoring of stereotactic ablative radiotherapy and immunotherapy in metastatic oligoprogressive lung cancer","volume":"25","author":"Zafra","year":"2024","journal-title":"Int J. Mol. Sci."},{"key":"10.1016\/j.critrevonc.2025.104853_bib97","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1097\/PPO.0000000000000436","article-title":"Radiation in the treatment of oligometastatic and oligoprogressive disease: rationale, recent data, and research questions","volume":"26","author":"Zayed","year":"2020","journal-title":"Cancer J."},{"key":"10.1016\/j.critrevonc.2025.104853_bib98","doi-asserted-by":"crossref","DOI":"10.1177\/17588359231183668","article-title":"Radiation and immune checkpoint inhibitors in the treatment of oligometastatic non-small-cell lung cancer: a practical review of rationale, recent data, and research questions","volume":"15","author":"Zayed","year":"2023","journal-title":"Ther. Adv. Med Oncol."},{"key":"10.1016\/j.critrevonc.2025.104853_bib99","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/j.ijrobp.2021.01.004","article-title":"Phase 3 multi-center, prospective, randomized trial comparing single-dose 24 gy radiation therapy to a 3-fraction SBRT regimen in the treatment of oligometastatic cancer","volume":"110","author":"Zelefsky","year":"2021","journal-title":"Int. J. Radiat. Oncol. *Biol. *Phys."},{"key":"10.1016\/j.critrevonc.2025.104853_bib100","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1007\/s00262-024-03720-7","article-title":"Oligo-residual disease in PD-1\/PD-L1 inhibitor-treated metastatic non-small cell lung cancer: incidence, pattern of failure, and clinical value of local consolidative therapy","volume":"73","author":"Zhang","year":"2024","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.critrevonc.2025.104853_bib101","doi-asserted-by":"crossref","first-page":"55","DOI":"10.2217\/fon-2021-0728","article-title":"Prognostic value of peripheral naive CD8+ T cells in oligometastatic non-small-cell lung cancer","volume":"18","author":"Zhao","year":"2022","journal-title":"Future Oncol."}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842825002410?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842825002410?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T03:17:59Z","timestamp":1777605479000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842825002410"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":101,"alternative-id":["S1040842825002410"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2025.104853","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Additions and subtractions of radiotherapy in patients with oligometastatic non-small cell lung cancer under the era of immunotherapy","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2025.104853","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"104853"}}